A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a starburst appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.
| Excerpt | Reference |
|---|
| "Lentigo maligna is the in situ phase of lentigo maligna melanoma, and if left untreated it may progress to invasive melanoma." | ( Ahmed, I; Berth-Jones, J, 2000) |
| "We have treated extensive lentigo maligna in two elderly patients with Imiquimod 5% (Aldara)." | ( Carre, JL; Guillet, G; Kupfer-Bessaguet, I; Leroy, JP; Misery, L; Sassolas, B, 2004) |
| "Basal and squamous cell carcinoma, lentigo maligna and lentigo maligna melanoma, dermatofibrosarcoma protuberans, and Merkel cell carcinoma are malignant lesions for which surgical excision is the recommended treatment." | ( Padgett, JK, 2005) |
| "30% to 35% of untreated lentigo malignas can progress into lentigo maligna melanoma." | ( Martín, T; Martínez, S; Ojeda, A; Vera, A, 2005) |
| "The treatment of lentigo maligna (LM) and lentigo maligna melanoma (LMM) is challenging due to lesion location, size, patient age, and potential for recurrence and spread." | ( Arlette, JP; Temple, CL, 2006) |
| "We report a patient with lentigo maligna, who was treated with the combination of topical imiquimod and cryosurgery, and review the rationale, which led us to design the present combined cryo-immunological treatment modality." | ( Bassukas, ID; Fotika, C; Gamvroulia, C; Nomikos, K; Zioga, A, 2008) |
| "Sustained clearance of lentigo maligna to date (26 months after treatment)." | ( Bassukas, ID; Fotika, C; Gamvroulia, C; Nomikos, K; Zioga, A, 2008) |
| "Periocular lentigo maligna was treated with topical imiquimod 5%." | ( Bianciotto, CG; Demirci, H; Shields, CL; Shields, JA, 2010) |
| "Periocular lentigo maligna seems to respond to topical imiquimod 5% treatment." | ( Bianciotto, CG; Demirci, H; Shields, CL; Shields, JA, 2010) |
| "The first choice of treatment for lentigo maligna (LM) is excision." | ( Kirtschig, G; Van Doorn, R; Van Meurs, T, 2010) |
| "We report a case of borderline lentigo maligna on the eyelid that proved difficult to treat with surgery and, when the patient deferred surgery for personal reasons, imiquimod 5% cream was used with complete resolution of the lesion and no recurrence so far over a 3-year period of follow-up." | ( Ayers, D; Kenealy, J; O'Neill, J, 2011) |
| "The key words "lentigo maligna,""lentigo maligna treatment,""lentigo maligna therapy," and "lentigo maligna therapeutic modalities" were used." | ( Choudhary, S; Giannakakis, G; McLeod, M; Nouri, K, 2011) |
| "Imiquimod has been used for treating lentigo maligna (LM) in selected cases when surgery is not an appropriate option because of functional or aesthetic impairment." | ( Alarcon, I; Alos, L; Carrera, C; Malvehy, J; Palou, J; Puig, S, 2014) |
| "The reported efficacy of imiquimod for lentigo maligna varies widely, without consensus on tumor or treatment factors that can impact tumor clearance." | ( Karia, PS; Mora, AN; Nguyen, BM, 2015) |
| "If left untreated, LM can progress to lentigo maligna melanoma (LMM)." | ( David, M; Foote, M; Noonan, C; Read, T; Schaider, H; Smithers, BM; Soyer, HP; Wagels, M, 2016) |
| "The current recommended treatment for lentigo maligna (LM) is surgical resection, which can cause significant scarring." | ( Barlow, R; Coleman, A; Craythorne, EE; Kai, AC; Mallipeddi, R; Richards, T, 2016) |
| "Records of all patients with lentigo maligna treated with our method of staged surgical excision between 2002 and 2011 were retrieved." | ( de Vries, K; Greveling, K; Koljenović, S; Munte, K; Prens, EP; Prens, LM; van Doorn, MB, 2016) |
| "A higher incidence of lentigo maligna (LM) recurrences on the nose was previously observed in our cohort after non-surgical treatment." | ( Greveling, K; Noordhoek Hegt, V; Prens, EP; van der Klok, T; van Doorn, MB, 2017) |
| "Treatment of lentigo maligna (LM) is challenging because of the potential functional and esthetic surgical sequelae." | ( Bossard, C; Denis Musquer, M; Dréno, B; Khammari, A; Nguyen, JM; Soenen, A; Vergier, B; Vourc'h, M, 2022) |
| "Patients from our unit with lentigo maligna or lentigo maligna melanoma treated with imiquimod 5% as monotherapy or in combination with surgery were included in this study." | ( Álvarez-Chinchilla, P; Bañuls-Roca, J; Hispán-Ocete, P; Poveda-Montoyo, I; Schneller-Pavelescu, L, 2022) |
| "Patients from our unit with lentigo maligna or lentigo maligna melanoma treated with imiquimod 5% as monotherapy or in combination with surgery were included in this study." | ( Álvarez-Chinchilla, P; Bañuls-Roca, J; Hispán-Ocete, P; Poveda-Montoyo, I; Schneller-Pavelescu, L, 2022) |
| "Treatment for peri-ocular Lentigo maligna showed a 56-86% complete treatment response and a 90% tolerability rate." | ( Daniel, C; Kaushik, M; Neumann, I; Patalay, R; Timlin, H, 2023) |
| "Local recurrence of lentigo maligna melanoma (LMM) and lentigo maligna (LM) continue to be challenging following surgical treatment and aftercare." | ( Behrens, V; Eckardt, J; Forchhammer, S; Häfner, HM; Kofler, K; Kofler, L, 2022) |
| "Imiquimod reduces the lentigo maligna surface after 1 month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome." | ( Bedane, C; Bens, G; Beylot-Barry, M; Bossard, C; Daude, M; Debarbieux, S; Denis, MG; Dinulescu, M; Dréno, B; Khammari, A; Le Duff, F; Leccia, MT; Legoupil, D; Machet, L; Maillard, H; Meyer, N; Monestier, S; Nguyen, JM; Vergier, B; Wierzbicka-Hainaut, E, 2023) |